Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Change in Total Nasal Symptom Score From Baseline to Day 14. [ Time Frame: Baseline to Day 14 ]
The 4-point (0=None, 1=Mild, 2=Moderate, and 3=Severe) intensity scale was summed across multiple symptoms (nasal congestion, rhinorrhea, nasal itching, and sneezing). Thus, the TNSS scores could range from 0 to 12, with higher scores indicative of greater severity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female participants aged 18 to 65 years with history of seasonal allergic rhinitis
Participants able to understand and willing to sign the informed consent form
Anotomical deviations of the nasal septum that significantly impair ventilation or airflow
Pregnant or nursing women
Positive serology for infectious disease (Hepatitis B or C, HIV) at screening
Parallel participation in another current investigational study, participation in a study within less than 30 days prior to study entry, or previous participation in this same study.